Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study.
Saved in:
| Title: | Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. |
|---|---|
| Authors: | Aronson R; LMC Diabetes and Endocrinology, East York, Canada., Frias J; National Research Institute, Los Angeles, California., Goldman A; Pfizer, Inc., Collegeville, Pennsylvania., Darekar A; Pfizer Ltd., Tadworth, UK., Lauring B; Merck & Co., Inc., Kenilworth, New Jersey., Terra SG; Pfizer, Inc., Andover, Massachusetts. |
| Source: | Diabetes, obesity & metabolism [Diabetes Obes Metab] 2018 Jun; Vol. 20 (6), pp. 1453-1460. Date of Electronic Publication: 2018 Feb 23. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1463-1326 |
|---|---|
| DOI: | 10.1111/dom.13251 |
